Bausch Health

Bausch Health Companies Inc. is a global, diversified pharmaceutical company that develops, manufactures, and markets a wide range of products, primarily in the therapeutic areas of gastroenterology, hepatology, neurology, dermatology, and eye health. Formerly known as Valeant Pharmaceuticals International, the company rebranded in 2018 to distance itself from past controversies and focus on its core brands like Salix, Ortho Dermatologics, and its majority stake in Bausch + Lomb. The company operates with a significant global footprint, selling products in over 90 countries. Its business model relies heavily on key blockbuster assets such as Xifaxan (rifaximin) for IBS-D and hepatic encephalopathy. Bausch Health is currently undergoing a multi-year strategic transformation, which includes the potential full separation of its eye-care business, Bausch + Lomb, and a focus on reducing its significant debt load through refinancing and asset optimization.